Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
1,001 - 10,000 - Monthly Reach
Unique listeners across all episodes (30 days)
5,001 - 25,000 - Active Followers
Loyal subscribers who consistently listen
501 - 5,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Pricing Under Pressure: What MFN Really Means for Global Strategy
Mar 3, 2026
39m 56s
Navigating Global Policy Shifts with Nikhil Taxak
Nov 27, 2025
26m 37s
Beyond the Headlines: Understanding MFN's True Impact on Market Access
Oct 2, 2025
19m 22s
Revolutionary Strategies in Orphan Drug Development with Isabel Rubio
Aug 28, 2025
18m 29s
Elevating launch excellence: The strategic value of early market access involvement with Lizzie Shanahan, Sanofi
Jun 26, 2025
30m 22s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 3/3/26 | Pricing Under Pressure: What MFN Really Means for Global Strategy | Most Favored Nation (MFN) pricing has taken over conversations at conferences, client meetings, and boardrooms alike, but what does it actually mean in practice? In this episode, we continue the conversation on evolving US pricing policy. Host Louise Bennett is joined by three of the Access Infinity team: Leigh Ann Bruhn, Louisa Byrne, and Richard Mee. Together, they discuss the current MFN landscape from multiple angles: US payer and policy, global pricing and modelling, and ex-US strategic ... | 39m 56s | ||||||
| 11/27/25 | Navigating Global Policy Shifts with Nikhil Taxak | In this episode we sit down with Nikhil Taxak, Head of Pricing and Market Access Data Analytics at Access Infinity, to explore the rapidly evolving market access landscape. From the US Most Favored Nation (MFN) policy and Germany's Medical Research Act to surprising developments in Japan's pricing thresholds, Nikhil breaks down how these changes are reshaping pricing and reimbursement strategies worldwide. The conversation covers emerging regional patterns across Europe, North America, and ... | 26m 37s | ||||||
| 10/2/25 | Beyond the Headlines: Understanding MFN's True Impact on Market Access | In this episode, we're joined by Louisa Oliver Byrne, Senior Consultant at Access Infinity. We learn about the complexities of the Most Favored Nation (MFN) policy and its implications for pharmaceutical market access. Louisa shares insights from her recent research on MFN, exploring how direct-to-consumer pricing models might actually play out in practice, and why the policy's stated goals don't always align with likely outcomes. From "brown bagging" concerns to payer behaviour shifts, this ... | 19m 22s | ||||||
| 8/28/25 | Revolutionary Strategies in Orphan Drug Development with Isabel Rubio | In this episode, we invite Access Infinity Partner, Isabel Rubio back to the podcast to explore the unique challenges and innovative solutions reshaping market access and pricing within rare disease. Isabel shares insights from her extensive experience with due diligence assessments in orphan drug development, discussing three transformative strategies that are revolutionising how companies prove value in ultra-rare diseases. From multi-domain endpoints and visual evidence to pay... | 18m 29s | ||||||
| 6/26/25 | Elevating launch excellence: The strategic value of early market access involvement with Lizzie Shanahan, Sanofi | In this insightful episode we speak with Lizzie Shanahan, Global Access AI Strategy Lead at Sanofi. With over six years' experience at Sanofi and a rich background in commercial roles, Lizzie shares her unique journey into the world of market access and how her diverse experience shapes her approach to launch excellence. The conversation explores exciting developments in the industry, including the evolution of digital technologies and AI. Lizzie shares thoughtful insights on finding the righ... | 30m 22s | ||||||
| 5/7/25 | Getting ready for the JCA: Why cross-functional collaboration matters with Silvy Mardiguian, BeiGene | In this episode, we speak with Silvy Mardiguian, Senior Director and Head of HEOR for Europe & New Markets at BeiGene. Silvy has been co-leading BeiGene’s preparedness and organisational readiness for the new Joint Clinical Assessment (JCA) framework, which is going to significantly change the EU HTA landscape. Silvy shares key insights into some of the learnings and challenges she has encountered during this process and highlights why strong cross-functional collaboration has been... | 18m 35s | ||||||
| 2/6/25 | The rise of multi-stakeholder capitalism in market access with Jie Shen, CSL | In this episode we chat with Jie Shen, who is Vice President Global Head Market Access at CSL. Having started her career in pharma before the market access function existed, Jie is an industry veteran. We cover the changes she's seen over the last 24 years, including multi-stakeholder capitalisation - what it means to Jie and why she feels it's important for market access leaders. The opinions shared in this podcast are Jie's own views. Send a text | 13m 37s | ||||||
| 1/21/25 | Authentic leadership in Market Access with Katrin Jack, Galderma | We're kicking off 2025 with a fantastic podcast episode featuring Katrin Jack, Global Access Strategy Head at Galderma and President of the Healthcare Businesswomen's Association Zürich-Zug Chapter. This episode covers a lot of ground, from the 'sliding doors' moment that led Katrin into market access, to why she feels it's important for leaders to understand their core values (and stay true to them). Like many of our podcast guests, Katrin has an obvious passion for market access... | 42m 03s | ||||||
| 12/12/24 | Market Access in emerging markets with Ezgi Erdogan, GSK | In this episode we speak with Ezgi Erdogan who is Oncology Market Access Director for Emerging Markets at GSK. In this discussion, we cover the unpredictability of emerging markets and the unique challenges this presents. Ezgi also shares her future predictions for access in emerging markets and talks about the importance of cross-functional collaboration in pharma to support the ever-changing landscape. The opinions shared in this podcast are Ezgi's own views. Send... | 15m 05s | ||||||
| 11/21/24 | Why Market Access requires unique thinking with UCB's Pauline Payen | In this episode, we sit down with Pauline Payen, Director and Global Payer Strategy Lead for UCB’s Early Portfolio. Pauline shares her pragmatic insights into navigating the complexities of global market access. Throughout her career, Pauline hasn't been shy of new opportunities, which has led to her taking on roles in commercial and marketing to expand her experience. In this discussion, we explore why market access is her passion. A field where, as she says, "What you do, can be lif... | 27m 41s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 10/17/24 | The role of resilience in market access with Rupert Gale from GSK | In this episode we're joined by GSK's Head of Market Access for General Medicines, Rupert Gale. Rupert has been in pharma for over 27 years and is still going strong! In this discussion, he shares what resilience means to him and why he feels it's an important skill for market access leaders to leverage. Rupert shares some wonderful stories and advice that many of us can relate to and learn from. He also reveals what's keeping him passionate about access and value as he continues his ... | 29m 06s | ||||||
| 9/26/24 | Exploring value demonstration in market access with Korinna Karampampa, CSL Behring | Korinna Karampampa, who is Director Market Access and Pricing at CSL Behring, joins this episode to share her views on sustainable economic development. Korinna shares what led her into market access and explains what drives her to think outside the box to build and demonstrate a product's current and future value. The opinions shared in this episode are Korinna’s own views and not representative of the organisation she is working for. Send a text | 14m 28s | ||||||
| 9/5/24 | Connecting the dots: Market access in the biotech industry with Ning Lu, Blueprint Medicines | In this episode we're joined by our first guest from Biotech - Ning Lu, who is Associate Director, International Pricing & Market Access at Blueprint Medicines. Ning shares her views on the complexities of market access and what makes the Biotech industry unique. She shares what inspired her to pursue a career in market access in biotechnology and why she feels it's a dynamic role and opportunity to 'connect the dots' with everything you learn. Ning references and recommend... | 16m 21s | ||||||
| 8/15/24 | What it takes to thrive as a strategic partner in market access with Marco Rauland, Merck KGaA | There’s no doubt that Market Access and Pricing leaders are fast becoming strategic partners in helping their wider organisations to understand the critical role of the function. In this episode, Marco Rauland from Merck KGaA joins us to explore this topic. Marco is Vice President Global Market Access and Pricing strategy, Pricing and Analytics. With over 25 years' experience in the field, he shares his views on the importance of clear communication when engaging all stakeholders and why MA&a... | 18m 05s | ||||||
| 8/8/24 | Yvonne Hilsky, Moderna, on why it's important to understand the building blocks of market access. | In this episode we're joined by Yvonne Hilsky who is Director of Market Access at Moderna. Having spent over 30 years in industry, Yvonne shares her views on what it takes to be successful in market access, including why making mistakes are an opportunity for growth. Yvonne explores why it's important to have strong foundations and understand the 'building blocks' of market access and shares great stories from the early stages of her career, which we're sure will resonate with ma... | 19m 25s | ||||||
| 7/31/24 | Raising awareness on Disability with Shubham Jadhav | In this special episode which coincides with Disability Pride Month, we're joined by Senior Analyst Shubham Jadhav. Shubham has Becker Muscular Dystrophy (BMD) which is a form of muscular dystrophy and causes progressive muscle weakness. Shubham is very passionate about raising awareness of rare diseases, disability, inclusivity and accessibility. He joins Keshav Nagaraja to share his story and what we can all be doing to help those with disabilities. It's an inspiring discussion whic... | 32m 58s | ||||||
| 7/18/24 | Exploring Canada's market access landscape with Sam Stankovic, Incyte Biosciences Canada | Sam is Head of Market Access Canada at Incyte Biosciences Canada and joins the podcast to discuss the evolving market access landscape in Canada. As part of his conversation with Louise, he describes the unique challenges that market access leaders in the country are facing. Useful resources referenced in this podcast: March 2024 - Canadian Health Policy Institute (Patented Medicines Expenditure in Canada 1990 – 2022) https://www.canadianhealthpolicy.com/product/patented-medicines... | 20m 16s | ||||||
| 7/11/24 | Market access challenges and changes: Joao Carrasco talks data, AI and predicting uncertainties | In this episode we're joined by Joao Carrasco, Director, Global Market Access Team at Bayer Pharmaceuticals. With a 12+ year career spanning both HEOR and Market Access functions, Joao shares his journey and how his strong HEOR background informs his current role. Joao also explores the key pressures and challenges market access teams are facing and his views on the trends shaping the future of market access. The opinions shared in this episode are Joao's own views and not repre... | 25m 31s | ||||||
| 6/20/24 | Sanofi's Becky Germino on communicating value, AI and the role of HEOR in supporting access & pricing leaders | In this episode we look at market access through a different lens. We're joined by Becky Germino who has extensive experience in HEOR across a broad range of pharma organisations. Becky joined Sanofi this year as HEVA, Neurology and Immunology Team Leader and explains the key priorities for HEOR teams and their role in working closely with market access to help them define and communicate patient value. The discussion also explores the role of AI for HEOR and market access teams&n... | 29m 51s | ||||||
| 3/21/24 | Sharing your market access story and demonstrating value with Biogen’s Adrian Harrington | Adrian Harrington, Senior Director Value and Access at Biogen, joins the podcast to discuss market access excellence – what it means to him, and the critical role visual communication is playing for market access leaders. Adrian also shares his views on what’s next for the market access function, detailing why leaders must embrace opportunities to demonstrate the value of market access and tell the story of their team’s success. Strong communication strategies are clearly important to Adrian ... | 23m 57s | ||||||
| 3/7/24 | Digitalisation of Market Access with Thomas Gilboy and Shravani Madishetti | In this special episode, Louise teams up with colleagues Thomas Gilboy and Shravani Madishetti from Access Infinity to explore the transformative impact of digital on market access. Shravani, APAC Pricing and Market Access Lead, highlights the efficiency and accuracy achieved through digital tools while Tom, Product Owner for Nuro, emphasises the importance of maximising the effectiveness of digital tools. Together, they offer valuable insights and practical guidance for navigating this evolv... | 24m 39s | ||||||
| 2/1/24 | Finding fun in Market Access with Khalid Mirza, Daiichi Sankyo | In the third episode of series 2, Louise interviews Khalid Mirza, Senior Director, Global Market Access & Pricing, Oncology at Daiichi Sankyo. They discuss Khalid's journey into market access, and how, for him, it's evolved into an exciting career path where science meets commercial. They also touch on the key themes shaping the future of market access, where Khalid's positive energy and passion for the function shines. The opinions shared in this episode are Khalid's ... | 29m 28s | ||||||
| 1/11/24 | Inspiring professional growth within Market Access with Nick Proctor | In this episode Louise teams up with Access Infinity Partner, Nick Proctor. Nick has been a consultant in the biopharmaceutical industry for over twenty years and shares his views on the hot topics and trends which he feels will have the biggest impact on market access in the coming years, also offering his insights on the themes which are 'hype'. Throughout his career Nick has also been responsible for training, coaching and mentoring others in global market access and pricing, and tal... | 24m 25s | ||||||
| 1/4/24 | Taking on new challenges in Market Access with David McConkey, Gilead Sciences | Welcome back to the Market Access Matters podcast! In the first episode of series 2, Louise interviews David McConkey, Virology and Oncology Global Value and Access Director at Gilead Services. Having started his career in consulting and then working across global and country roles, David has a breadth of experience in market access. In this discussion he shares his experiences of taking on new challenges, leading teams into new territories and what he's learnt along the way. &nbs... | 20m 15s | ||||||
| 9/21/23 | Women Leaders in Market Access: Katie Gardner, Astellas, talks digital, building high performing teams and recognising that ideas can come from anywhere | In this episode we’re joined by Katie Gardner, who is Head of Global Market Access Excellence at Astellas. We hear Katie’s insights on the changing landscape of market access and what it demands from teams in terms of agility and innovation. She talks about how digital technology can empower teams to evolve with the ever-changing demands of the market and what her team are doing to drive market access excellence. Katie is passionate about building high performing teams and discusses the... | 23m 17s | ||||||
Showing 25 of 32
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
3 placements across 3 markets.
Chart Positions
3 placements across 3 markets.